Journal and book references
Alonso Martinez JL, Abinzano Guillen ML, et al. Low-molecular-weight heparin for the treatment of acute pulmonary thromboembolism. Comparison with unfractionated intravenous heparin. An Med Interna. 2005;22:177-81.
Brophy DF, Dougherty JA, Garrelts JC, et al. Venous thromboembolism prevention in acutely ill nonsurgical patients. Ann Pharmacother. 2005;39:1318-24.
Dunn CJ, Goa KL. Enoxaparin. A pharmacoeconomic appraisal of its use in thromboembolic prophylaxis after total hip arthroplasty. Pharmacoeconomics. 1996;10:179-90.
Frydman AM, Bara L, Le Roux Y, et al. The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol. 1988;28:609-18.
Gallay S, Waddell JP, Cardella P, Morton J. A short course of low-molecular-weight heparin to prevent deep venous thrombosis after elective total hip replacement. Can J Surg. 1997;40:119-23.
Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005;106:401-7.
Grosset AB, Spiro TE, Beynon J, Rodgers GM. Enoxaparin, a low-molecular-weight heparin suppresses prothrombin activation more effectively than unfractionated heparin in patients treated for venous thromboembolism. Thromb Res. 1997;86:349-54.
Huisman MV, Bounameaux H. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention. Semin Vasc Med. 2005;5:276-84.
Jaffer AK, Brotman DJ, Michota F. Current and emerging options in the management of venous thromboembolism. Cleve Clin J Med. 2005;72 Suppl 1:S14-S23.
Merli GJ. Low-molecular-weight heparins versus unfractionated heparin in the treatment of deep vein thrombosis and pulmonary embolism. Am J Phys Med Rehabil. 2000;79 Suppl 5:S9-S16.
Pendleton R, Wheeler M, Rodgers G. Venous thromboembolism prevention in the acutely ill medical patient: a review of the literature and focus on special patient populations. Am J Hematol. 2005;79:229-37.
Prandoni P, Carnovali M, Marchiori A, Galilei Investigators. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Arch Intern Med. 2004;164:1077-83.
Samama MM, Cohen AT, Darmon J-Y et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med. 1999;341:793-800.
Siddiqui M, Asif A, Wagstaff, Antona J. Enoxaparin. A review of its use as thromboprophylaxis in acutely ill, nonsurgical patients. Drugs. 2005:65:1025-36.
van Den Belt AG, Prins MH, Lensing AW et al. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev. 2000;(2):CD001100. Cochrane Database Syst Rev 2004;(4):CD001100.
Verhaeghe R. Extended prophylaxis of venous thromboembolism in major orthopaedic surgery. Acta Orthop Belg. 2005;71:255-9.
Wartski M, Collignon MA. Incomplete recovery of lung perfusion after 3 months in patients with acute pulmonary embolism treated with antithrombotic agents. THESEE Study Group. Tinzaparin ou Heparin Standard: Evaluation dans l'Embolie Pulmonaire Study. J Nucl Med. 2000;41:1043-8.
Books for the general public
Deep Vein Thrombosis Anatomical Chart. Chicago (IL): Anatomical Chart Company; 2002.
Deep Vein Thrombosis – A Medical Dictionary, Bibliography and Annotated. Research Guide to Internet References: San Diego (CA): Icon Health Publications; 2004.
Deep Vein Thrombosis (Martin Dunitz Medical Pocket Books). London: Informa Healthcare; 1997.
Deep Vein Thrombosis, The Silent Killer. London: Quay Books; 1996.
Hall LA, Eccles M. Case Study of an Inter-professional and Inter-organisational Programme to Adapt, Implement and Evaluate Clinical Guidelines for the Risk Assessment and Prevention of Deep Vein Thrombosis in Hospital In-patients. Newcastle upon Tyne: Centre for Health Services Research; 1999. Report no. 99.